Wikipedia -WSS

Wikipedia

author：hotspot 2025-08-19 12:10:10 - browse：26

Two hands hold a box of four Wegovy pens — first opinion coverage from STAT — Cydni Elledge/The New York Times

The news about anti-obesity drugs keeps getting better. In November, data presented at the American Heart Association meeting added cardiovascular benefit to value in combating obesity and diabetes. This comes on the heels of news that Novo Nordisk halted a clinical trial to test Wegovy’s impact on renal function early because the results they were seeing were so strong.

Yet beneath the hype lies a real fear. Unless we reverse the rising tide of metabolic syndrome, Medicare will be crushed, with tens of millions of Americans having shorter, harder lives. The new drugs offer the first real chance to deploy at scale treatments to halt a seemingly unstoppable trend.

That will be costly. But so is the status quo. Medicare spending on people with advanced metabolic disease is sobering. Beneficiaries with two or more of the costliest conditions — diabetes, heart failure, or chronic kidney disease — comprise just 10% of beneficiaries, according to the NIH’s Renal Data System 2022 Annual Data Report. Yet they account for 25% of total costs. Those with all three conditions are 2% of beneficiaries but almost 7% of costs. And remember, the current cohort of Medicare beneficiaries turned 65 when obesity and diabetes rates were lower, meaning unless we do something dramatic, and fast, these percentages will balloon.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How to save PrEP access — and even expand it
Next article： Readout LOUD podcast: How biotech is using artificial intelligence

WSS

The problem with charging patients to message their doctors

Industry veterans launch new biotech VC with $310M

Biogen Alzheimer’s drug launch off to slow start

Biogen Alzheimer’s drug launch off to slow start

Novo Nordisk obesity pill bests Wegovy in early trial

Why did Pfizer dish out millions for a Super Bowl ad?

focus

Wikipedia

knowledge

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

The dental labor crisis is a moment of opportunity

Affirmative action in medical school literally saved lives

What we’ve learned from the Aduhelm mess

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Medicare threatens to cut off funding for HCA's Mission hospital

Virginia high school admissions case could be legal follow

Biden report: The neurospychology of memory and aging

Drug repurposing or repositioning? The language matters

RSV shot was 90% effective at preventing hospitalizations in kids

hotspot

A disappointing year of Humira biosimilars

Headspace, Meta partner to launch VR meditation app for Quest

Biogen Alzheimer’s drug launch off to slow start

The problem with charging patients to message their doctors

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Gilead might be held responsible for not developing a drug

focus

entertainment

focus

knowledge